Family Hx, Mutation Position Key Variables in BRCA1/2 Cancer Risk

Share this content:
Family Hx, Mutation Position Key Variables in <i>BRCA1/2</i> Cancer Risk
Family Hx, Mutation Position Key Variables in BRCA1/2 Cancer Risk

WEDNESDAY, June 21, 2017 (HealthDay News) -- Breast cancer risk peaks around the 40s for BRCA1 mutation carriers and around the 50s for BRCA2 carriers, with family history and mutation location significant factors in determining individual risk, according to a report published in the June 20 issue of the Journal of the American Medical Association.

Researchers tracked 9,856 women with BRCA1 and BRCA2 mutations. These included 5,046 cancer-free women and 4,810 women previously diagnosed with breast or ovarian cancer. During an average follow-up period of five years, 426 of the women were diagnosed with breast cancer, 109 with ovarian cancer, and 245 with breast cancer in the second breast.

The researchers found that the increase in breast cancer risk rose quickly in early adulthood and then plateaued, typically for the rest of a woman's life. For women with a BRCA1 mutation, the plateau occurred around ages 31 to 40. For those with BRCA2 mutations, the plateau occurred about five to 10 years later. The researchers concluded that 72 percent of BRCA1 carriers will develop breast cancer by age 80, and 44 percent will develop ovarian cancer by that age. For BRCA2 carriers, 69 percent of women will develop breast cancer by age 80 and 17 percent of women will develop ovarian cancer by the same age.

The team also found that breast cancer risk increased with increasing number of first- and second-degree relatives diagnosed as having breast cancer. Risk was also higher if mutations were located outside versus within the regions bounded by positions c.2282-c.4071 in BRCA1 and c.2831-c.6401 in BRCA2. The authors conclude that these findings "demonstrate the potential importance of family history and mutation location in risk assessment."

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Zika Does Not Appear to Last in Semen As Long As Thought

Zika Does Not Appear to Last in Semen ...

More research is needed to better inform public health recommendations

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke Risk

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke ...

I-131 therapy group showed no significantly higher risk of ischemic or hemorrhagic stroke

Higher Odds of Infection With Reduced Kidney Function

Higher Odds of Infection With Reduced Kidney Function

Study finds excess community-acquired infections incidence in individuals with mild to severe CKD

is free, fast, and customized just for you!

Already a member?

Sign In Now »